Nisa Investment Advisors LLC Purchases 247 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...
Sarepta’s Elevidys Phase 3 Study Raises Concerns: Kapoor Issues Sell Rating Amid Market Applicability and Control Group Disparities
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...
Hold Rating Maintained Amidst Revance Therapeutics Acquisition Uncertainty
Mizuho Securities analyst Uy Ear has maintained their neutral stance on RVNC stock, giving a Hold rating on January 17.Invest with Confidence: ...
Sarepta could be down on patient death in FDA database, says RBC Capital
RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...
Q4 2024 ConnectOne Bancorp Inc Earnings Call
Hello, and thank you for standing by. My name is Bella, and I will be your conference operator today. At this time, I would like to welcome everyone to ConnectOne Bancorp, Inc. fourth quarter 2024 ...
JD Supra15h
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...
precisionmedicineonline13h
Roche Looks Forward to Itovebi Approval in Europe Amid Steady Q4 Revenue Growth
The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.